News and research before listening to CNBC and others. Claim your free 1 week trial at StreetInsider Premium here.
A scientific paper recently published in Nature Biotechnology reveals new research on how we track and control the immunity of T-cell patients in SARS-CoV-2, taking advantage of the unique features of the Hyris System ™. The study is the result of a joint effort by an international research team from the Icahn School of Medicine in Mount Sinai, Singapore Duke-NUS Medical School, Synlab and Hyris Laboratory Diagnostic Service Providers.
LONDON, June 15, 2022 (GLOBE NEWSWIRE) – With more than 460 million global cases so far, 6 million of which have resulted in death, the SARS-CoV-2 pandemic of COVID-19 turned out to be a crisis serious global scale. In this worrying scenario, the unprecedented effort of the international scientific community is even more remarkable and led, in record time, to the deployment of mRNA-based vaccines and viral vectors. With more than 10 billion total vaccine doses administered worldwide, vaccination campaigns have already begun to alleviate this global crisis. In order to maximize the effectiveness of the vaccine, the efficacy and duration of protective immunity should be systematically evaluated and monitored as widely as possible.
A team of internationally renowned medical scientists recently published an article related to Nature Biotechnology, which addresses the efficacy and sensitivity of a new type of assay for detecting SARS-CoV-2 cellular immunity.
“Until now, antibody testing has been the typical, if not the only, clinical criterion commonly used to measure the immune response to SARS-CoV-2,” said Antonio Bertoletti, a professor at Duke-NUS Medical. School. “Both humoral (antibody) and cellular immune responses work in a coordinated manner to achieve long-term protection against viral infections. Antibodies are important in preventing infection, protecting the body from disease, while immunity “Cellulite is essential for the elimination of virus-infected cells, thus helping to fight the disease itself,” concludes Professor Bertoletti.
Therefore, according to the study, measuring the response of T cells is a new disruptive approach to the fight against SARS-CoV-2. An individual negative for an antibody test could still be protected by responsive T cells.
This new study shows the relevance of a quantitative PCR approach for T-cell testing, thanks to the joint effort with SYNLAB, one of the world’s leading providers of laboratory diagnostic services, and Hyris, a company global biotechnology focused on AI-driven genetics. analysis.
The research took advantage of Hyris’ characteristic technology, the disruptive Hyris System ™.
“These highly scalable screening methods will be especially important in controlling the magnitude and duration of functional cellular immunity to emerging variants, helping to prioritize revaccination strategies in vulnerable populations,” said Cristina Lapucci, Head of Genetics and Molecular Biology of SYNLAB Italy.
“We have been very committed to putting our system at the service of such prestigious partners,” says Stefano Lo Priore, founder and CEO of Hyris. “Many medical institutions around the world have already embraced our technology, embracing the unprecedented simplicity, connectivity and scalability of the Hyris SystemTM.”
The rapid deployment of SARS-CoV-2 vaccines to a large proportion of the population now suggests new approaches to measuring the duration of the immune response and the potential need for vaccine enhancements should be assessed.
“The tests used in our study are based on the quantification of CXCL10 MRNA after incubation of whole blood with specific SARS-CoV-2 peptides. The levels of armature CXCL10 Transcripts are strongly correlated with IFN-gamma produced by activated antigen-specific T cells, which serves as a proxy to detect cellular immunity in subjects recovered by COVID-19 and vaccinated against SARS-CoV- 2 “says Ernesto Guccione, PhD, Professor of Oncology. Pharmacological Sciences and Sciences, at Icahn Mount Sinai.
“This is especially important after the emergence of SARS-CoV-2 variants such as Omicron that evade most of the neutralizing ability of antibodies, but not that of T cells,” continues Megan Schwarz, a student. postgraduate at Icahn Mount Sinai and first grade. author of the manuscript. “Accurate measurement of cellular responses underlying virus protection therefore represents a crucial parameter of immune defense.”
“Solutions already on the market are usually based on traditional fluorescence methodologies commonly used in the immunological field,” adds Jordi Ochando, PhD, Adjunct Professor of Oncology, Medicine (Nephrology) and Pathology, Molecular and Cellular. Medicine based in Icahn Mount Sinai. “This research proves it CXCL10 The mRNA expression confirms the data obtained with traditional methods (i.e. ELISpot) compared to the naive, convalescent subject of COVID-19 and vaccinated against SARS-CoV-2, ”he concludes.
This study could be a key solution to give more support to the scientific community that plays a strategic role in meeting this global challenge.
Contact a Hyris expert to find out how to act beyond your current diagnostic capabilities at [email protected].
Related images
Image 1: Hyris continues to support T cell research
3D rendering of a T cell attacking a Coronavirus. Hyris is committed to supporting the immunology sector as a new frontier in the fight against COVID-19 and other pathologies
This content was broadcast through Newswire.com’s press release distribution service.
-
Hyris continues to support T cell research